Vaxart(VXRT) - 2024 Q2 - Quarterly Results

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a nextgeneration approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 8, 2024 — Vaxart, Inc. (Nasdaq: VXRT) today annou ...